Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0OXDSB
ADC Name
B-B4-SPP-DM1
Synonyms
B-B4 SPP DM1
   Click to Show/Hide
Organization
ImmunoGen, Inc.; Biotest AG
Drug Status
Investigative
Indication
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Investigative
Drug-to-Antibody Ratio
3.5
Structure
Antibody Name
Anti-CD138 mAb B-B4
  Antibody Info 
Antigen Name
Syndecan-1 (SDC1)
  Antigen Info 
Payload Name
Mertansine DM1
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
Combination Type
Mertansine
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 77.45
%
MOLP-8 cells
Plasma cell myeloma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 77.45% (Day 20) Positive CD138 expression (CD138 +++/++)
Method Description
MOLP-8 cells (1.5x107 cells per mouse) suspended in a 50:50 mixture of serum free media and matrigel were injected subcutaneously in the area under the right shoulder in 100 ul. Nine groups (n=6) were treated with a single intravenous injection of ADCs, each at doses of 250 ug/kg.
In Vivo Model MOLP-8 CDX model
In Vitro Model Plasma cell myeloma MOLP-8 cells CVCL_2124
References
Ref 1 Immunoconjugates targeting cd138 and uses thereof; 2009-07-02.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.